The medication is indicated for adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater in the presence of at least one weight-related comorbidity such as pre-diabetes, type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea
In this regard, linagliptin-mediated CV effects can occur both in response to better glycemic control, as well as by mechanisms independent of glycemic control in animal models of pre-diabetes [35, 42, 44,45,46,47,48]
One of the exciting benefits researchers have discovered about semaglutide is its ability to aid in weight loss
This could make oral semaglutide more accessible, though its important to remember that orforglipron is not yet commercially available
Al final, lo que determina la satisfaccin es la suma de estabilidad tcnica, atencin receptiva y una poltica de responsabilidad que ponga al usuario en el centro